Is biopharma getting better at accelerated approval conversions?
Amid ongoing pressure to reform the FDA’s fast-track pathway, signs emerge that the criticism is being heard.
Crucial clinical events for the smaller players
Data are due in the fourth quarter for Aldeyra, Aeglea and Radius, among other small developers.
Asco 2021 movers – PDS wins, but big pharma reigns
PDS and Spectrum rise, while Black Diamond, Alpine, Harpoon and Macrogenics disappoint, and others ride on big pharma’s coattails.
Asco 2020 movers – cell therapy companies dominate the risers
Adaptimmune and Allogene led numerous cell therapy companies higher over the Asco period, while Cytomx and Arvinas suffered the biggest losses.
